Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market
Rising Number of Spinal Cord Injuries
According to a report published by the Association for Spinal Injury Research, Rehabilitation and Reintegration (Aspire, UK), ~2,500 people are diagnosed with spinal cord injuries (SCIs) annually in the UK. Currently, ~50,000 people are living with SCIs in the country. An elevated number of cases is attributed to emerging motocross and motorcycling competitions as the most popular sporting activities in the UK, as per the National Institute of Health (NIH) report. With rising motor sporting activities among the youth and senior age group population, there is an increase in the incidence of SCIs among the participants of these events. SCIs have life-changing impacts on the injured patients and their families. Owing to the rising incidence of SCIs, results in at least one readmission of the patient every year. This is because SCIs are not treated at once. The causes of rehospitalization include respiratory and urinary tract infections, and fractures occurring during motorcycling sports activities.
The London Spinal Cord Injury Center (LSCIC) is 1 of the 11 organizations in the UK dedicated to treating SCI patients. At the LSCIC, patients undergo a rehabilitation program that takes years and is best delivered through lifelong intervention. With rising SCI and the availability of a well-developed infrastructure in treatment centers providing rehabilitation programs, demand for spinal cord stimulation devices is surging in specialized or rehab centers, which fuels the market growth.
Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market: Segmental Overview
The “Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market” is segmented on the basis of product type, application, end user, and region. Based on product type, the spinal cord stimulation devices for chronic pain market is bifurcated into rechargeable and non-rechargeable. The rechargeable segment held the largest share of the market in 2022 and the same segment is anticipated to register the highest CAGR during 2022–2030.
Based on application, the spinal cord stimulation devices for chronic pain market is segmented as failed back syndrome, complex regional pain syndrome, degenerative disk disease, and others. The complex regional pain syndrome segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022–2030. Complex regional pain syndrome (CRPS) involves prolonged pain and inflammation occurring due to an injury or other medical events such as surgery, trauma, stroke, and heart attack. CRPS can occur anywhere in the body, usually affecting the arm, leg, hand, or foot. It is more likely to occur in females and can occur in anyone at any age, with the inflammation approaching a peak after 40 years of age. The majority of CRPS cases are caused due to damaged or improperly functioning small peripheral C-fiber nerve fibers, which carry pain messages to the brain. CRPS often goes undiagnosed with the development of tiny clots, sometimes blocking blood flow to the nerve and injuring it.
Based on end user, the spinal cord stimulation devices for chronic pain market is segmented as hospitals, ambulatory surgery centers, and others. The hospitals segment held a larger market share in 2022 and the same segment is anticipated to register the highest CAGR for the forecast period 2020-2030. Spinal cord stimulation devices are widely adopted in hospitals to treat patients suffering from spinal cord injuries (SCIs). These devices are implanted via a minor surgery that is often carried out as an outpatient procedure, followed by an overnight stay of patients in the hospital. The hospital infrastructure is well-equipped to successfully use implantable devices such as spinal cord stimulators, which transmit mild electrical pulses directly into the nerve fibers of the patient after implantation, resulting in reduced chronic pain.
Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market: Competitive Landscape and Key Developments
Boston Scientific Corp, Abbott Laboratories, Medtronic Plc, Curonix LLC, Biotronik SE & Co KG, Nevro Corp, Nalu Medical Inc, Cirtec Medical Corp, and Synapse Biomedical Inc; are among the leading companies operating in the Europe and Middle East spinal cord stimulation devices for chronic pain market. These players are focusing on expanding and diversifying their market presence and acquiring a novel customer base, thereby tapping prevailing business opportunities in the Europe and Middle East spinal cord stimulation devices for chronic pain market. Many market players are launching their innovative products in the Europe and Middle East spinal cord stimulation devices for chronic pain market with advanced features.
